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Inducible cAMP early repressor (ICER) has been described as a transcriptional repressor
isoform of the cAMP response element modulator (CREM). Here we report that ICER is
predominantly expressed in Th17 cells through the IL-6–STAT3 pathway and binds to the Il17a
promoter, where it facilitates the accumulation of the canonical enhancer RORgt. In vitro
differentiation from naive ICER/CREM-deﬁcient CD4þ T cells to Th17 cells is impaired but
can be rescued by forced overexpression of ICER. Consistent with a role of Th17 cells in
autoimmune and inﬂammatory diseases, ICER/CREM-deﬁcient B6.lpr mice are protected
from developing autoimmunity. Similarly, both anti-glomerular basement membrane-induced
glomerulonephritis and experimental encephalomyelitis are attenuated in ICER/CREM-deﬁ-
cient mice compared with their ICER/CREM-sufﬁcient littermates. Importantly, we ﬁnd ICER
overexpressed in CD4þ T cells from patients with systemic lupus erythematosus.
Collectively, our ﬁndings identify a unique role for ICER, which affects both organ-speciﬁc and
systemic autoimmunity in a Th17-dependent manner.
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T
he role of cAMP-response element modulator (CREM) in
T-cell differentiation is complex and not completely
understood. CREM has many alternatively spliced tran-
script variants, and their relative expression affects T-cell
differentiation. A relationship between CREM and Th17 cells
has been proposed1. Genome-wide analyses of Th17 transcription
regulatory network revealed the induction of CREM among other
genes, and silencing of CREM was associated with reduced Th17
differentiation2.
Numerous reports have claimed that interleukin (IL)-17 has an
important role in the pathogenesis of autoimmune diseases,
including systemic lupus erythematosus (SLE)1,3–5. Expression of
CREMa, a repressor isoform of CREM, is increased in CD4þ
T cells from SLE patients, and forced expression of CREMa in
human T cells enhances IL-17A expression6. Moreover,
mice overexpressing CREMa in T cells display increased
IL-17 production and severe skin inﬂammation, as well as mild
lupus-like disease7.
Inducible cAMP early repressor (ICER) is a splice variant of
CREM8. In contrast to other isoforms of CREM, ICER has an
alternative transcription initiation site and is induced by a unique
alternative promoter (P2)9. Because ICER has no transcriptional
activation domains, it functions as a powerful repressor of cAMP-
induced CRE-mediated transcription. Previous papers have
shown that ICER inhibits T-cell activation, Th1/Th2 cell
differentiation and suppresses the production of proinﬂa-
mmatory cytokines10,11; however, whether ICER is involved in
the generation of Th17 cells is not known.
Here we demonstrate that ICER is the predominant CREM
isoform expressed in Th17 cells in both mice and humans. ICER
is induced by IL-6 via STAT3 signalling and enhances RORgt
accumulation on the Il17a promoter. Mice deﬁcient in ICER/
CREM develop less anti-glomerular basement membrane-
induced glomerulonephritis (AIGN) and experimental encepha-
lomyelitis (EAE), and B6.lpr ICER/CREM-deﬁcient mice develop
less autoimmunity and lupus nephritis. The relevance of these
new ﬁndings in human disease is underscored by the increased
expression of ICER in T cells from SLE patients. Overall, ICER
controls organ-speciﬁc and systemic autoimmunity by controlling
IL-17 production.
Results
ICER is induced in Th17-polarized murine CD4 T cells. To
further understand the role of CREM in Th17 differentiation, we
asked which CREM isoforms are expressed during in vitro
Th17-polarizing conditions. Using western blotting we investi-
gated the expression of CREM isoform induction in ICER/
CREM-sufﬁcient and -deﬁcient T cells cultured under
Th17-polarizing conditions. We noted ao20 kDa CREM band to
be induced by day 3 (Fig. 1a, left) in ICER/CREM-sufﬁcient but
not in ICER/CREM-deﬁcient T cells (Fig. 1a, right ﬁrst and
second lanes) pointing that this band was an isoform of CREM.
Because the size of the detected CREM was o20 kDa, we
assumed that it represented ICER. Because CREM has various
isoforms and it is impossible to identify speciﬁc isoform(s) by
conventional mass spectrometry, we generated plasmids that
overexpress each of the two typical ICER isoforms, that is, ICER
and ICERg. When we transfected these plasmids into HEK-293T
cells and compared the size of those molecules with theo20 kDa
CREM, both overexpressed ICER bands (majority ICERg) ﬁt
perfectly to the o20 kDa CREM (Fig. 1a, right). We conclude
that the o20 kDa CREM induced in Th17 cells is an isoform of
ICERg or perhaps ICER.
Next we polarized T cells under Th17, Th1, Th2 and Treg
conditions, and we noted that ICER was present in signiﬁcant
amounts only when cells were driven towards Th17 rather than
any of the other three conditions (Fig. 1b). To conﬁrm that ICER
is induced under Th17 conditions, we cultured T cells from
B6.IL-17GFP mice under the same Th17 culture conditions and
sorted green ﬂuorescent protein (GFP)-positive (IL-17A produ-
cing) and GFP-negative (IL-17A non-producing) cells. As seen in
Fig. 1c, ICER is expressed primarily by IL-17A-producing cells
and not by non-IL-17A-producing cells (Fig. 1c). We asked
whether IL-17A-producing T cells from MRL/lpr mice before
in vitro polarization also express ICER as a result of ongoing
stimulation in vivo. Indeed, as shown in Fig. 1d, IL-17A-
producing T cells from MRL/lpr mice expressed more ICER than
naive CD4 MRL/Mpj mice.
ICER/CREM deﬁciency reduces in vitro Th17 differentiation.
Although ICER is known to affect Th1 and Th2 in vitro polar-
ization, it remains unclear how ICER/CREM deﬁciency
contributes to Th17 and Treg differentiation. We assessed the
impact of ICER expression in T cells cultured in vitro under Th1,
Th2, Th17 and Treg polarized conditions. As shown in Fig. 2a,
IL-17A-producing cells were reduced in Th17-polarized
cells from ICER/CREM-deﬁcient compared with those from
ICER/CREM-sufﬁcient cells, yet, we could not see any signiﬁcant
differences in T cells cultured under other polarizing conditions.
We determined the expression of each master transcription
factor, Gata3, Tbet, Rorc and Foxp3 in T cells cultured under Th1,
Th2, Th17 and Treg, respectively. We did not ﬁnd any differences
in the expression of Tbet and Foxp3 but we found increased
expression of Gata3 and decreased Rorc gene expression in
ICER/CREM-deﬁcient mice (Fig. 2b). These data are in agree-
ment with a previous report according to which ICER/CREM-
deﬁcient T cells tend to differentiate towards Th2 more than
ICER/CREM-sufﬁcient T cells11,12. Decreased numbers of
IL-17A-producing cells among Th17-polarized ICER/
CREM-deﬁcient T cells were conserved when several IL-6
concentrations were used (Fig. 2c). When we measured the
expression of Th17-related genes, ICER/CREM-deﬁcient T cells
displayed less Il23r, Il17a and Il17f expression (Fig. 2d).
To prove further the role of ICER in Th17 differentiation we
transfected ICER/CREM-deﬁcient T cells with ICER and ICERg
expression vectors and polarized them under Th17 conditions. As
seen in Fig. 2g, transfection of either of the ICER isoforms
resulted in increased IL-17 GFPþ T-cell induction relative to
those that received empty plasmid, providing further support that
ICER promotes Th17 differentiation. Taken together, these data
indicate that ICER/CREM promotes Th17 differentiation,
whereas it inhibits Th2 differentiation and does not affect
Th1 and Treg differentiation.
ICER is induced by IL-6 through STAT3 signalling. Combi-
nation of IL-6 and transforming growth factor beta (TGFb) can
differentiate T cells into Th17 cells, where transduction of IL-6
receptor activity occurs through STAT3 and that of TGFb
through SMAD3 (refs 4,13). To address the relative impact of
these stimuli we added to anti-CD3 and anti-CD28 Ab-stimulated
T cells IL-6, TGFb, or IL-6 and TGFb. ICER was induced only if
IL-6 was present in the culture (Fig. 3a). This ﬁnding was
conﬁrmed by blocking IL-6 or TGFb signal transduction by
adding STAT3 or SMAD3 inhibitors in T cells cultured under
polarizing conditions. The presence of STAT3 inhibitor inhibited
the induction of ICER in a dose-dependent manner while the
presence of a SMAD3 inhibitor had no effect (Fig. 3b). Further-
more, when we cultured naive CD4þ T cells from CD4creþ
STAT3ﬂ/ﬂ mice under Th17-polarizing conditions we could not
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detect any ICER induction proving the importance of STAT3
signalling in the induction of ICER.
To follow-up on this data, we searched for deﬁned STAT3-
binding sites in the ICER/CREM gene. Within the
91 kbp sequence (chr18: 3,251,045–3,342,901) spanning 
15 kbp upstream to þ 5.2 kb downstream from the ICER/CREM
locus (MGI: 88495) one putative STAT3-binding sequence
(BS1: þ 586/þ 594, 30-TTCCTGGAA-50 from the ICER
transcription start site) was identiﬁed by using the match
module of gene regulation (http://www.gene-regulation.com).
To investigate whether STAT3 regulates ICER expression at the
transcriptional level we cloned the ICER promoter into a
luciferase reporter system. This promoter region includes a
CRE-binding site in the p2 promoter ( 116/ 53), two
putative CRE-binding sites (þ 573/þ 580; þ 639/þ 646) and
a putative STAT3-binding site (þ 586/þ 594) in the ﬁrst intron
(Fig. 3d). As shown in Fig. 3e, the cloned promoter region that
deﬁnes the STAT3-binding site possessed signiﬁcantly
increased transcriptional activity when the cells were cultured
under Th17-polarizing conditions compared with Th0-non-
polarized conditions. This activity was completely abrogated in
cells transfected with a mutated STAT3 site-mutated promoter
(Dþ 586) (Fig. 3d,e), indicating that IL-6 induces ICER
expression directly through STAT3 signal transduction.
Day 1 2 3
CREMτ
CREMα
ICER
ICE
R/C
RE
M
+/+
ICE
R/C
RE
M
–
/–
ICER/CREM+/+
CREM
Day 3
β-actin
NS
IL-
17
GF
P
+
IL1
7G
FP
–
β-actin
ICERβ-actin
ICER
Th1 Th2 Th17 Treg
120
80
60
20
30
40
(kDa)
40
Em
pty
ICE
R
ICE
Rγ
293T
17
40
120
80
60
20
30
40
(kDa)
(kDa)
17
40
(kDa)
Density
Density
5,985 3,391
4,431  4,201
β-actin
ICER
Na
ive
 M
RL
/M
pj
Th
17
 M
RL
/lpr
17
40
(kDa)
MR
L/lp
r
MR
L/M
pj
0
1
2
3
4
R
at
io
 
o
f d
en
sit
y 
(IC
ER
/β
-
a
ct
in
)
*
Non-
specific
bands
(NS)
a
b c
d
Figure 1 | ICER is expressed in IL-17-producing murine T cells. (a, left) CREM and b-actin expression in Th17-polarized ICER/CREMþ /þ murine CD4þ
T cells was measured by western blotting at the indicated time points. (a, right) CREM expression on day 3 in Th17-polarized ICER/CREMþ /þ murine
CD4þ Tcells (right, far left), Th17-polarized B6.ICER/CREM / mice CD4þ Tcells (right, second left), empty plasmid transfected HEK-293Tcells (right,
third left), ICER-overexpressing plasmid-transfected HEK-293T cells (right, third right) or ICERg-overexpressing plasmid-transfected HEK-293Tcells (right,
second right) was measured by western blotting. Data are representative of four experiments. (b) ICER/CREM and b-actin expression on day 3 of Th0-,
Th1-, Th17- and Treg-polarized ICER/CREMþ /þ mice CD4þ T cells was measured by western blotting. Data are representative of three experiments.
(c) ICER/CREM and b-actin expression of FACS-sorted GFPþ (IL-17A-producing cells) or GFP (IL-17A-non-producing cells) in Th17-polarized B6. IL-17A
GFP ICER/CREMþ /þ CD4þ T cells on day 3 were measured by western blotting. Data are representative of three experiments. (d) ICER and b-actin
expression of FACS-sorted IL-17A-producing cells from 18-week-old MRL/lpr mice or naive CD4 T cells from 18-week-old MRL/Mpj control mice was
determined by western blotting. A representative (of three) blot is shown (left) and densitometric readings from three experiments are shown on the right
(*Po0.05; mean±s.e.m., n¼4). See Supplementary Fig. 1 for uncropped scans of the western blot.
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Figure 2 | Compromised Th17 cell differentiation in ICER/CREM / mice. Naive CD4þ Tcells from B6.ICER/CREMþ /þ mice or B6.ICER/CREM /
mice were polarized for 3 days as indicated condition. (a) Representative ﬂow plots of intracellular expressions of IFNg or IL-4 and IL-17A (left), the
percentages of cells (right) and polarized in indicated condition were measured by ﬂow cytometry (*Po0.05; mean±s.e.m., n¼ 3). See Supplementary
Fig. 2A for FACS gating strategy. (b) Real-time PCR analysis of indicated gene expressions in those differentiated cells, relative to b-actin (n¼ 3) (*Po0.05;
mean±s.e.m., n¼ 3). (c) The percentage of IL-17-producing cells in Th17-polarized T cells with different concentrations of IL-6. Cumulative results of four
independent experiments are shown (****Po0.0001, *Po0.05; mean±s.e.m., two-way analysis of variance (ANOVA)). (d–f) Real-time PCR analysis of
(d) Il17a, (e) Il17f and (f) Il23r in Th17-polarized Tcells on day 3. A proﬁle representative of three mice is shown (*Po0.05; mean±s.e.m., n¼ 3). (g) Empty
vector (Empty), ICER-expressing (ICER) or ICERg-expressing (ICERg) plasmids were transfected to Th17-polarized T cells from indicated strains of IL-17A
reporter mice on day1, and the percentage of IL-17-producing cells was measured by ﬂow cytometry. A proﬁle representative of three mice is shown on the
right (*Po0.05; mean±s.e.m., two-way ANOVA, Bonferroni, #Po0.05 two-tailed t-test, n¼ 3). See Supplementary Fig. 2B for FACS gating strategy.
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ICER enhances RORct accumulation. Because previously we
had shown that CREMa, which is a suppressive isoform of
CREM, bound directly to human IL-17A promoter and increased
human IL-17A promoter activity14, we considered that
ICER could affect similarly Il17a promoter activity. To this end
we generated FLAG-tagged ICER-overexpressing plasmids
(FLAG-ICER and FLAG-ICERg) and transfected them into
ICER/CREM-deﬁcient T cells, which we polarized under Th17
conditions. Transfection of either of the ICER isoforms resulted
in increased IL-17 GFPþ T-cell induction compared with those
that received empty plasmid (Supplementary Fig. 2).
Furthermore, as shown in Fig. 3f, ICER accumulated at the
Il17a promoter region. The promoter activity of IL-17A decreased
after disruption of the CRE-binding site ( 116/ 109) in the
IL-17A promoter, suggesting the importance of this site in the
il-17A gene transcription (Fig. 3g,h). Finally, we asked whether
ICER binding inﬂuenced RORgt accumulation at the ROR-
binding element ( 116/ 111). We found that RORgt
accumulation at the ROR-binding element was increased when
we introduced ICERg-overexpressing vector compared with
empty vector (Fig. 3i). Collectively, in the process of Th17 cell
differentiation in vitro, ICER is induced by IL-6 though a STAT3
signalling pathway, binds directly to the CRE-binding site
of the IL-17A promoter and enriches RORgt accumulation at
the ROR-binding element.
ICER/CREM deﬁciency limits AIGN in mice. Given that
ICER/CREM deﬁciency had greatly impacted on in vitro Th17
cell differentiation, we proceeded to evaluate the relevance of
ICER/CREM expression in IL-17-dependent inﬂammatory
conditions. Because the development of kidney damage in AIGN
depends on Th17 cells, and IL-17 determines the severity of this
induced disease13,15, we induced AIGN disease in 9- to 11-week-
old male ICER/CREM-deﬁcient and -sufﬁcient mice. As shown in
Fig. 4a,b, histological sections from ICER/CREM-deﬁcient mice
showed less glomerulonephritis, tubulointerstitial inﬂammation,
vasculitis and less protein cast formation compared with those in
ICER/CREM-sufﬁcient mice. Accordingly, a signiﬁcant reduction
in proteinuria was observed in ICER/CREM-deﬁcient mice
compared with wild-type counterparts (Fig. 4c). Furthermore,
when we examined cell inﬁltration in the diseased kidney, ICER/
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CREM-deﬁcient mice had fewer inﬁltrating CD4þ T (CD45þ
CD90.2þCD4þ cells; Fig. 4d), IL-17A- (CD45þCD90.2þ
CD4þ IL-17Aþ cells; Fig. 4e) and interferon gamma (IFNg)-
(CD45þCD90.2þCD4þ IFNgþ cells; Fig. 4f) producing cells
than ICER/CREM-sufﬁcient mice. Collectively, ICER/CREM
deﬁciency protects against disease progression in a model of
AIGN.
ICER/CREM deﬁciency ameliorates EAE. To further document
the role of ICER/CREM in in vivo IL-17-dependent pathology, we
induced EAE in 9- to 11-week-old ICER/CREM-sufﬁcient and
-deﬁcient mice by immunizing them with myelin oligodendrocyte
glycoprotein (MOG35–55). Disease progression in ICER/CREM-
deﬁcient mice was remarkably reduced including lower clinical
scores and less body weight changes in ICER/CREM-deﬁcient
mice compared with wild-type littermates (Fig. 5b,c). Histological
sections of spinal cords showed signiﬁcantly decreased cell inﬁl-
tration and demyelization in ICER/CREM-deﬁcient mice
(Fig. 5a). The reduction of inﬁltrating cells was conﬁrmed by ﬂow
cytometry analysis of T cells extracted from spinal cords of
diseased mice. Since the number of inﬁltrated T cells was reduced
in spinal cord of ICER/CREM-deﬁcient mice, the absolute
numbers of CD4þ (CD45þCD90.2þCD4þ ; Fig. 5d), IL-17A-
(CD45þCD90.2þCD4þ IL-17Aþ ; Fig. 5e) and IFNg-producing
cells (CD45þCD90.2þCD4þ IFNgþ ; Fig. 5f) were reduced in
the spinal cords from ICER/CREM-deﬁcient mice as compared
with those from the spinal cords from ICER/CREM-sufﬁcient
counterparts, which reﬂects the decreased disease severity of
ICER/CREM-deﬁcient mice. To conﬁrm that this difference is
IL-17-related, we immunized ICER/CREM-sufﬁcient and -deﬁ-
cient mice with MOG35–55 and draining lymph nodes were
extracted on day 8. Isolated cells from the lymph nodes were
further cultured in ex vivo with MOG for 3 days. IL-17A/F and
IFNg concentration were measured by enzyme-linked immuno-
sorbent assay. As shown in Fig. 4, IL-17A/F production was
decreased in ICER/CREM-deﬁcient mice, whereas IFNg
production was not signiﬁcantly different (Fig. 5g,h). This further
points to the importance of ICER/CREM in the generation of
Th17 cells and the production of IL-17.
ICER/CREM deﬁciency abrogates lupus disease in B6.lpr mice.
CREMa, another repressor isoform of CREM, when over-
expressed in lupus-prone mice leads to increased lupus-like
autoimmune disease in a Th17-related manner7,16. Since ICER/
CREM deﬁciency affected Th17 differentiation in vitro and in two
different Th17-related disease models, we considered that ICER/
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CREM deﬁciency would delay or protect lupus-prone mice form
developing disease. We examined the effect of genetic ICER/
CREM depletion on the development of spontaneous lupus by
crossing ICER/CREM-deﬁcient mice with lupus-prone B6.MRL-
Faslpr/J (B6.lpr) mice (both in the C57BL/6J background). We
studied female ICER/CREM-deﬁcient B6.lpr mice at 28 weeks of
age and found that they displayed smaller spleens and cervical
lymph nodes compared with ICER/CREM-sufﬁcient B6.lpr mice
(Fig. 6a,b). Immunostaining analysis revealed less deposition of
complement 3 (C3) in the glomeruli of ICER/CREM-deﬁcient
B6.lpr compared with that in ICER/CREM-sufﬁcient B6.lpr mice
(Fig. 6c). Serum levels of anti-dsDNA antibody, proteinuria and
double-negative T cells (CD3þCD4CD8 cells), and serum
IL-17 were also signiﬁcantly reduced in the ICER/CREM-
deﬁcient mice (Fig. 6d–g). When we examined cell inﬁltration
in the kidneys, ICER/CREM-deﬁcient mice had fewer
CD45þ -inﬁltrating lymphocytes (CD45þ per 105 events),
T cells (CD45þCD90.2þ ) and IL-17A-producing cells
(CD45þCD90.2þ IL-17Aþ ) than ICER/CREM-sufﬁcient mice
(Fig. 6h). Furthermore, as shown in Fig. 6i, the survival curve
indicated a signiﬁcantly prolonged lifespan in B6.lpr.ICER/
CREM-sufﬁcient mice (median survival day; 279.5 days for
ICER/CREM-sufﬁcient mice and 361.0 days for ICER/CREM-
deﬁcient mice; P¼ 0.0044, Gehan–Breslow–Wilcoxon test).
Collectively, ICER/CREM deﬁciency rescues multiple lupus
characteristics and extends the lifespan of B6.lpr mice.
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ICER is increased in human Th17 cells and SLE T cells. Since
we found that ICER controls Th17-related experimental inﬂam-
mation and affects lupus-like manifestations of lupus-prone mice,
we sought evidence that it impacts inﬂammatory mechanisms in
human autoimmunity. We sorted peripheral blood mononuclear
cells from healthy donors into memory Th1 cells, memory Th2
cells, memory Th17 cells and Treg cells by ﬂow cytometry and
compared ICER expression in each population (Fig. 7a). We did
not detect ICER expression in any of the T-cell subsets before
stimulation (Supplementary Fig. 4). However, after 12 h of acti-
vation with anti-CD3 and anti-CD28 Ab, ICER was present at
statistically signiﬁcant amounts only in Th17 cells and not in any
of the other three subsets (Fig. 7b). Finally, we stimulated CD4þ
T cells with anti-CD3 and anti-CD28 Ab for 4 days and deter-
mined the levels of ICER expression by western blotting. As seen
in Fig. 7c, SLE T cells express more ICER than normal T cells.
Collectively these data suggest that ICER is induced not only in
murine but also in human Th17 cells and that its levels are
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increased in T cells from SLE patients, suggesting a role of ICER
in human disease.
Discussion
Although the canonical second messenger cAMP was ﬁrst
described as a potent negative regulator of T-cell immune
function17, recent reports have shown conﬂicting effects of
cAMP-related transcription factors on signal transduction and
T-cell differentiation. For example, CREB, a well-characterized
cAMP-responding transcription factor, has been proposed as a
Th17-promoting factor18 while other studies have emphasized its
ability to enhance regulatory T-cell differentiation and Foxp3
transcription19,20. CREM, another important cAMP-related
transcription factor, is tightly regulated at the epigenetic and
post-transcriptional levels. Alternative splice variants of the
primary CREM gene generate isoforms that exert opposing
effects on target gene expression compared with the full-length
proteins17. It appears though that the relative abundance of
CREM splice variants in different tissues and organs accounts for
speciﬁcity of the control of target gene expression. Understanding
the expression and the function of the different CREM isoform(s)
during the development of an immune response is thus
warranted.
Here we demonstrate a novel important role of ICER in the
generation of Th17 cells and in the development of IL-17-
related diseases in mice, including AIGN, EAE and SLE.
Although previous reports suggested that ICER exerts a
suppressive function in effector T cells10,11, we provide
evidence demonstrating that ICER is the most prevalent
CREM splice variant expressed during Th17 differentiation
and is preferentially expressed during Th17 generation
compared with other T helper subsets. We show that ICER is
involved in Th17 T-cell generation and is implicated in Th17/
IL-17-dependent autoimmune diseases.
Th17 differentiation requires the presence of IL-6 and its
transducing signalling partner STAT3. Our ﬁndings provide
evidence showing that ICER is a downstream partner of the IL-6/
STAT3 signalling pathway. Moreover, induction of ICER during
Th17 differentiation is independent of TGFb. This suggests that
ICER may be involved in the induction of pathogenic Th17 T
cells, which are generated in the absence of TGFb (ref. 21).
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IL-17 is important for the development of human and murine
inﬂammatory pathology4,22–24. Here we present strong evidence
that ICER/CREM is required for the expression of both organ-
speciﬁc and systemic autoimmunity. Lack of ICER/CREM
mitigates the development of AIGN as measured histologically
and clinically. Importantly, the number of IL-17-producing cells
in the kidney of ICER/CREM knockout mice is signiﬁcantly
diminished. Similarly, lack of ICER/CREM decreases EAE clinical
and histopathologic severity, as well as the frequency of
peripheral IL-17-producing cells. Of interest, T cells from
draining lymph nodes of ICER/CREM-deﬁcient mice display
normal IFNg production, but a limited production of IL-17,
pointing out a predominant effect of ICER/CREM on Th17
differentiation. In the absence of ICER/CREM, B6.lpr lupus-
prone mice display less systemic autoimmunity (anti-dsDNA
antibody) and renal pathology. This phenotype is linked to
decreased serum levels of IL-17 levels and to reduced numbers of
IL-17-producing cells in the kidney. These results underscore the
importance of ICER/CREM in the production of IL-17 and
autoimmune disease pathogenesis25–27.
In humans we show that Th17 CD4þ T-cell-differentiated
subset express higher level of ICER than Th1, Th2 and Treg
subsets. More importantly, we observed increased expression of
ICER in CD4þ T cells isolated from SLE patients, underscoring
the translational value of our ﬁnding. SLE patients display
increased serum levels of IL-17A, expanded frequency of IL-17-
producing T cells in the peripheral blood and a massive
inﬁltration of Th17 cells in organs involved by the disease, like
the kidneys28,29. Furthermore, IL-17A levels correlate with SLE
disease activity. Sera from patients with SLE show increased levels
of IL-6 (ref. 30), and STAT3 (ref. 31) is elevated in SLE T cells,
abnormalities that could account for the augmented expression of
ICER.
Robust activation of the cAMP-related signalling pathway
inhibits T-cell activation17 while precise control of the ratio of
cAMP-related transcription factors favours a differentiation
towards a Th17 phenotype18. Since ICER negatively regulates
cAMP-related transcription, ICER may play a major role in this
ﬁne-tuning process. Since it has been reported that levels of
cAMP are increased in ICER/CREM-deﬁcient mice32, and cAMP
is known to regulate glycolysis and glycolysis plays a critical role
in Th17 cell differentiation, we speculate that ICER/CREM affects
the glycolysis pathway. In SLE, both CREMa overexpression and
induced ICER act in concert to promote a pro-inﬂammatory
Th17 phenotype, by allowing increased RORgt accumulation.
In conclusion, we have identiﬁed ICER as a novel requisite
determinant of Th17 cell generation. It acts downstream of
STAT3, and after its binding to the IL-17 promoter, it enhances
the accumulation of the canonical Il17 transcription factor
RORgt. Importantly, genetic elimination of all ICER/CREM
isoforms suppressed the development of organ-speciﬁc and
systemic autoimmunity. The translational importance of our
work is highlighted by our ﬁndings showing that ICER expression
is increased in SLE T cells, as well as in human Th17 memory
cells. Our ﬁndings identify a unique role for ICER, which impacts
both organ-speciﬁc and systemic autoimmunity in a Th17-
dependent manner.
Methods
Human samples and cell lines. Patients who fulﬁlled the criteria for the diagnosis
of SLE as set forth by the American College of Rheumatology33 and healthy
individuals were enrolled. The BIDMC Institutional Review Board approved the
study protocol (2006-P-0298). Informed consent was obtained from all study
subjects. The disease activity for each patient was calculated using the clinico-
laboratory index SLE Disease Activity Index 34. Age-, sex- and ethnicity-matched
healthy individuals were chosen as controls (Supplementary Table 1). Peripheral
venous blood was collected in heparin-lithium tubes, and total human T cells were
puriﬁed as described previously35. In short, T cells were isolated by negative
selection (RosetteSep, Stem Cell Technologies) before density gradient puriﬁcation
(Lymphoprep, Nycomed). HEK-293T cells were purchased from American Type
Culture Collection (ATCC; Manassas, VA) and has been tested for mycoplasma by
ATCC.
Mice. SV129/Bl6.ICER/CREM /mice were originally cloned by Guenther
Schuetz, DKFZ Heidelberg36. Animals were crossed to C57BL/6J mice for over nine
generations to transfer the ICER/CREM / locus to the B6 background. Female
B6.MRL-Faslpr/J (B6.lpr), C57BL/6-Il17atm1Bcgen/J (IL-17GFP), STOCK Tg
(Cd4-cre)1Cwi/BﬂuJ (CD4creþ ), MRL/MpJ-Faslpr/J and B6.129S1-Stat3tm1Xyfu/J
(STAT3ﬂ/ﬂ) mice were purchased from The Jackson Laboratory. B6.lpr.ICER/
CREM / mice were made by crossing B6.ICER/CREM / mice with B6.lpr
mice. CD4creþ . STAT3ﬂ/ﬂ mice were made by crossing STAT3ﬂ/ﬂ mice with
CD4creþ mice. B6.ICER/CREM / .IL-17GFP mice were made by crossing
B6.ICER/CREM / mice with IL-17GFP mice. Animals were killed at the end of
their 8–12 weeks of life for in vitro culture experiments and indicated week for
in vivo experiments. All mice were maintained in an SPF animal facility (Beth Israel
Deaconess Medical Center). Experiments were approved by the Institutional
Animal Care and Use Committee of BIDMC. All mice were genotyped to validate
claimed strain.
Single-cell isolation. Spleens and lymph nodes were excised and single-cell
suspensions were obtained. Kidneys were perfused with PBS and digested with
collagenase type IV (100 mgml 1) (Worthington Biochemical) in Hank’s balanced
salt solution (HBSS) for 30min (37 C). Inﬁltrating lymphocytes in spinal cords
were isolated as previously described37. Brieﬂy, spinal cords were digested with
collagenase type IV (100 mgml 1) in HBSS for 20min (37 C). Cell suspensions
from digested spinal cords were subjected to density separation using Optiprep
density gradient medium (Sigma-Aldrich) followed by ﬂow cytometry.
In vitro T-cell differentiation. Naive CD4þ T cells were puriﬁed by mouse
CD4þCD62Lþ T Cell Isolation Kit II (Miltenyi Biotec). Puriﬁed naive T cells were
stimulated with plate-bound goat anti-hamster antibodies, soluble anti-CD3
(0.25 mgml 1,145-2C11; Biolegend) and anti-CD28 (0.5 mgml 1, 37.51; Biole-
gend) for Th0-non-polarized condition culture. In addition to Th0-non-polarized
condition, following stimulation was used for each polarized condition: IL-12
(20 ngml 1; R&D Systems) and anti-IL-4 (10mgml 1, C17.8; Biolegend) for Th1;
IL-4 (100 ngml 1; R&D Systems), anti-IL-12 (10 mgml 1; Biolegend) and anti-
IFNg (10mgml 1, XMG1.2; Biolegend) for Th2; IL-6 (3 ngml 1 or indicated
concentration; R&D Systems), TGF-b1 (0.3 ngml 1; R&D Systems), anti-IL-4
(10 mgml 1, C17.8; Biolegend) and anti-IFNg (10 mgml 1; XMG1.2; Biolegend)
for Th17; and IL-2 (20 ngml 1; R&D Systems), TGF-b1 (3 ngml 1; R&D
Systems), anti-IL-4 (10 mgml 1, C17.8; Biolegend) and anti-IFNg (10 mgml 1,
XMG1.2; Biolegend) for Tregs. For signal transduction studies, STA21 (STAT3
inhibitor; Santa Cruz Biotechnology) and SMAD3 inhibitor (SIS3; Santa Cruz
Biotechnology) were added to cultures on day 0.
Western blotting. Cell lysate was separated on NuPAGE 4–12% Bis-Tris Gel
(Life Technologies) and proteins were transferred to a nitrocellulose membrane.
Following antibodies were used: anti-CREM1 Ab (clone X-12, Santa Cruz, 1:500);
Stat3 Mouse mAb (clone 124H6, Cell Signaling, 1:500); Phospho-Stat3 (Tyr705)
Mouse mAb (clone 3E2, Cell Signaling, 1:500); anti-b-actin (clone AC-74, Sigma-
Aldrich, 1:10,000); goat anti-mouse IgG coupled with horseradish peroxidase
(catalogue# sc-2005, Santa Cruz, 1:3,000); and goat anti-rabbit IgG coupled with
horseradish peroxidase (catalogue# sc-2004, Santa Cruz, 1:3,000). The ECL system
(Amersham) was used for detection.
Flow cytometry. Following antibodies were used for ﬂow cytometry analysis: for
mouse, CD4 (clone GK1.5); CD8a (clone 53-6.7, 1:100); CD19 (clone 605, 1:100);
CD25 (clone PC61, 1:100); CD44 (clone IM7, 1:100); CD45 (clone 30-F11, 1:100);
CD62L (clone MEL-14, 1:100); CD90.2 (clone 53-2.1, 1:100); IL-17A (clone JC11-
18H10.1, 1:50); IFNg (clone XMG1.2, 1:50); and IL-4 (clone 11B11, 1:50) were
purchased from BioLegend. CD3a (clone 17A2, 1:100) and Foxp3 (clone FJK-16s,
1:50) were purchased from eBioscience. For human, CD45RA (clone HI100, 1:100),
CD25 (clone BC96, 1:100), CD127 (clone A019D5, 1:100), CCR4 (clone L291H4,
1:100), CCR6 (clone G034E3, 1:100) and CXCR3 (clone G025H7, 1:100) were
purchased from BioLegend. A CD4 (clone SK3, 1:100) was purchased from
eBioscience. A 7AAD (surface) or a Zombie Aqua Fixable Viability Kit (intracel-
lular) staining was performed for eliminating dead cells (BioLegend). Surface
staining was performed on ice for 20–30min. Absolute cell numbers were
calculated on the basis of the percentage of each cell population. For intracellular
staining, collected cells were stimulated for 4 h in culture medium with phorbol
myristate acetate (500 ngml 1; Sigma-Aldrich), ionomycin (1.4 mgml 1; Sigma-
Aldrich) and monensin (1 ml ml 1; BD Biosciences), except Foxp3 detection.
Cytoﬁx/Cytoperm and Perm/Wash buffer (BD Biosciences; for IL-17A/IL-4/IFNg
staining) or Mouse Regulatory T-cell staining kit (eBioscience; for Foxp3 staining)
were used for ﬁxation and permeabilization. All ﬂow cytometry data were acquired
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on a BD LSRII and analysed with FlowJo. All procedures were performed according
to the manufacturer’s instructions.
Western blotting for formalin-ﬁxed and FACS-sorted cells. Cells from
18-week-old MRL/lpr mice and MRL/Mpj mice spleen and lymph node were
stimulated in culture medium contains phorbol myristate acetate (500 ngml 1;
Sigma-Aldrich), ionomycin (1.4 mgml 1; Sigma-Aldrich) and monensin
(1ml ml 1; BD Biosciences) for 3 h. Collected cells were stained by a Zombie Aqua
Fixable Viability Kit, CD4, CD8, CD90.2, CD19, CD62L antibodies (for surface)
and IL-17A antibodies (for intracellular) as described before. After staining,
ZA-CD19-CD62L-CD8-Th1.2þ IL-17þ cells (for IL-17-producing cells) and
ZA-CD19-CD62LþCD8-CD4þTh1.2þ IL-17- cells (for naive CD4 T cells) were
subsequently sorted by BD FACS Aria II (ﬁve lasers 355, 405, 488, 561 and 640 nm;
BD Bioscience). Sorted cells were washed with PBS, then lysed in Extraction
Buffer EXB Plus (Qproteome FFPE Tissue Kit, Qiagen), which contains 6%
b-mercaptoethanol (Sigma-Aldrich), on ice for 5min, followed by heat denatura-
tion at 100 C for 20min. Then samples were incubated at 80 C for 2 h with
vortexing every 2min, followed by centrifuging them for 15min in cold room.
A volume of 5 ml of NuPAGE LDS Sample Buffer (4 ) (Invitrogen) was added to
the supernatant containing the extracted proteins.
ELISA. Following ELISA kits were used: ELISA MAX Deluxe SET Mouse IL-17A/F;
IFN-g and IL-2 (BioLegend); mouse anti-dsDNA IgG ELISA (Alpha Diagnostic
Intl. Inc.); Parameter Creatinine Kit (R&D Systems); and Mouse Albumin ELISA
Quantitation Set (Bethyl Laboratories). All procedures were performed according to
the manufacturer’s instructions.
RNA isolation and quantitative PCR. Total RNA was prepared using the Qiagen
RNeasy Mini kit (Qiagen) and RNA was reverse transcribed into cDNA using the
EcoDry Premix (Oligo dT) (Clontech) according to the manufacturer’s instruc-
tions. Quantitative PCR was performed by using LightCycler 480 SYBR Green
I Master (Roche). Target genes were detected using intron-spanning primers.
Gene expression was assessed by comparative CT method. Primers information is
described in the Supplementary Table 2.
ICER subset-overexpressing vectors. Plasmid contains wild-type ICER coding
sequence (corresponding to GenBank. AJ311667.1) was kindly gifted by Dr Shogo
Endo38, and subcloned into pIRES2-DsRed-Express vector (Clontech Laboratories
Inc.). Following oligonucleotide sequences were used: 50-TGATCTCGAGCATGG
CTGTAACTGGAGATG-30 ; and 50-TGCTGGATCCCGTTACTCTACTTTATGG
CAAT-30 . ICERg overexpression vector and N0-FLAG-tagged overexpressing
vectors were generated using Q5 site-directed mutagenesis kit (New England
Biolabs). Following oligonucleotide sequences were used: 50-CTGCCACAGGT
GACATGCCAAC-30 ; and 50-CAGTTTCATCTCCAGTTACAGC-30 . For
generating N0-FLAG-tagged overexpressing plasmid, FLAG sequence
(DYKDDDDK) were inserted N0 terminal of ICER-overexpressing plasmid or
ICERg-overexpressing plasmid. Following oligonucleotide sequences were used:
50-GACGATGACAAGGCTGTAACTGGAGATGAAAC-30; and 50-ATCCT
TGTAGTCCATCCTCGAGATCTGAG-30 . All constructs were validated by DNA
sequencing. All procedures were performed according to the manufacturer’s
instructions.
Transfection of overexpressing vectors. For transfection to HEK-293T cells,
plasmids were transfected to 60–80% conﬂuent HEK-293T cells by poly-
ethylenimine ‘Max’ (Polysciences, Inc.) according the manufacturer’s protocol and
cultured 2 days in culture media. For ICER-overexpressing experiments in murine
primary T cells, cells were collected 1 day after starting culture and empty vector,
ICER-overexpressing plasmid, or ICERg-overexpressing plasmid were transfected
using the Amaxa Mouse T Cell Nucleofector Kit with the X-001 programme
(Amaxa) according to the manufacturer’s protocol. The supernatant of each culture
was saved in 4 C during transfection and recovery. After 4 h recovery at 37 C,
cells were again cultured in those supernatant for 2 days. The efﬁcacy of the
transfection always exceeds 10%.
Luciferase reporter constructs. To generate the mouse ICER P2 promoter
luciferase promoter construct, we TA-cloned the p2 promoter from genomic
DNA of C57BL/6 mouse using KOD XL DNA Polymerase (Thomas Scientiﬁc)
and pGEM-T easy Vector System (Promega). Following primers were used:
Ms_pICER_F, 50-CACTGTGGAGCCTGGTATGT-30 ; and MS_pICER_R, 50-CCC
ACTTGTCACTAGGCAGG-30 . Using TA-cloned mouse ICER P2 promoter, a
PCR was performed with primers Mlu1_mpICER_F; 50-GTTAACGCGTCACTG
TGGAGCCTG-30 and Bgl_mpICER_R; 50-CGATAGATCTCCCACTTGTCA
CTAG-30 for adding restriction enzyme sites (Mlu1 and Bgl2 for 50-end and 30-end,
respectively). Then this amplicon was ligated into pGL3 vector using T4 DNA
Ligase (M202; New England BioLabs) to generate ICER_p2_pGL3_vector.
Q5 site-directed mutagenesis kit (New England BioLabs) was used for site-directed
mutagenesis. Following DNA oligonucleotide was used for site-directed
mutagenesis at the þ 586/þ 594 STAT3-binding site (TTCCTGGAA) within
ICER_p2_pGL3_ vector; 50-TCGTGTTTCAGCGGGGAA-3 and 50-ATGTAA
TGACGTCAGCCC-30 . The pGL4 mIL-17A promoter (pGL4 mIL-17 0.6 kb
promoter) was a gift from Warren Strober (Addgene plasmid # 20126)39. Q5
site-directed mutagenesis kit (New England BioLabs) was used for site-directed
mutagenesis. Following DNA oligonucleotide was used for site-directed
mutagenesis at the  116/ 109 CRE site (TGACCTCA) within pGL4 mIL-
17A_vector; 50-TTTGAGGATGGAATCTTTACTCAAATG-30 and 50-
GCACAGAACCACCCCTTT-30. All Sequences were veriﬁed (Genewiz). All
procedures were performed according to the manufacturer’s instructions.
Luciferase assay. Luciferase reporter plasmid was transfected using the Amaxa
Mouse T Cell Nucleofector Kit with the X-001 programme (Amaxa) on day 2 of
culture. Each reporter experiment included 200 ng renilla luciferase construct as an
internal control. Luciferase activity was quantiﬁed using the Promega Dual Luci-
ferase Assay System (Promega) on day 3 of culture according to the manufacturer’s
instructions.
Chromatin immunoprecipitation assays. Freshly isolated naive CD4þ T cells
from B6. ICER/CREM / mice were cultured in Th17 polarizing condition for 3
days. Plasmids were transfected as described above on day 1. Collected cells were
lysed and ChIP assay was performed using MAGnify Chromatin Immunopreci-
pitation System (Invitrogen). For RORgt immuno-precipitation, Ds-Redþ vector-
transfected cells were sorted by ﬂow cytometry before ChIP assay. ANTI-FLAG
antibody produced in rabbit (Sigma-aldrich), and anti-Human/Mouse ROR
gamma (t) Puriﬁed AFKJS-9; eBioscience) were used for immunoprecipitation.
Following primer pairs were used: 50-CGTCATAAAGGGGTGGTTCT-30 and
50-TTACGTCAAGAGTGGGTTGG-30 for CRE/ROR-binding element; and
50-GAACTGGAAATGAAACCTTTGG-30 and 50-TTTCATCACAGCAACCCT
TC-30 for non-CRE site. All procedures were performed according to the
manufacturer’s instructions.
AIGN model. A volume of 50 ml Freund’s Incomplete Adjuvant (Thermo Scien-
tiﬁc), 250 mg HR37a Mycobacterium tuberculosis powder (Difco) and 0.1mgml 1
Rabbit IgG (Pierce) were emulsiﬁed and injected in each ﬂank subcutaneously in
8-week-old male mice 3 days before starting the experiment. On day 0, 100 ml
Rabbit anti-mouse GBM serum (kindly gifted from T. N. Mayadas, Pathology of
Harvard medical school, Boston) was injected intravenously. Urine samples were
collected on day 0, 7, 14 and 21 of the experiment, and urinary albumin and
creatinine were quantiﬁed by ELISA as above. On day 21, kidneys were excised
from the mice and processed for ﬂow cytometry and histology. Clincial and
histologic scores were evaluated in a blind manner.
EAE disease model. On day 0, 8-week-old male mice were immunized
subcutaneously with 50 mg MOG35–55 peptide emulsiﬁed in complete Freund’s
adjuvant (Sigma) containing 4mgml 1 M. tuberculosis extract (H37Ra; Difco)
distributed between the two hind ﬂanks. On days 0 and 2, 150 ng per mouse
pertussis toxin (List Biological Laboratories) was given by intraperitoneal injection.
Mice were monitored and weighted daily until day 28 of the experiment, and
clinical scores were given as follows: 1, limp tail; 2, hindlimb paresis; 3, hindlimb
paralysis; 4, tetraplegia; and 5, moribund. Clinical and histologic scores were
evaluated in a blind manner.
Priming assay for MOG immunizations. Mice were immunized with 50 mg
MOG35–55 peptide emulsiﬁed in complete Freund’s adjuvant into both ﬂanks. Eight
days after the immunization, inguinal lymph nodes were excised.
Histological staining and analysis. For EAE models, sections from 10% formalin-
ﬁxed spinal cords were stained with haematoxylin and eosin and luxol fast blue.
Histology was scored by an investigator blinded to experimental group. Spinal cord
sections were scored by an investigator blinded to experimental group as follows: 0,
no inﬁltration (o50 cells); 1, mild inﬁltration of nerve or nerve sheath (50–100
cells); 2, moderate inﬁltration (100–150 cells); 3, severe inﬁltration (150–200 cells);
and 4, massive inﬁltration (4200 cells). For AIGN model and B6.lpr mice, sections
from 10% formalin-ﬁxed kidneys were stained with periodic acid-schiff. Renal
lesions were evaluated blindly by a nephro-pathologist as described previously14 for
B6.lpr mice or criteria described in http://www.bolderbiopath.com/systemic-lupus-
erythematosus-sle/ for AIGN model. Sections of frozen kidneys were stained with
Hoechst 33258 (Life technologies; 1:1,000) and Fluorescein-conjugated goat IgG to
mouse complement C3 (MP Biomedicals; 1:200). Then specimens were analysed
with a Nikon Eclipse Ti confocal microscope. Images were analysed with EZ-C1
v.3.7 and Image J.
Assessment of ICER expression from isolated human T cells. Isolated
T cells from SLE patients and healthy controls were stimulated with pre-coated
1 mgml 1 anti-CD3 (clone OKT3, BioXcell) and 1 mgml 1 anti-CD28 (clone 28.2,
BioLegend) for 4 days.
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Human primary CD4þ lymphocyte subset sorting. Peripheral blood mono-
nuclear cells were isolated from Trima-collar (Blood Donor Center, Boston
Children Hospital) by density gradient centrifugation (Lymphoprep, Nycomed).
CD4þ T cells were enriched using CD4þ T-cell isolation kit II (Miltenyi Biotec).
After staining, primary lymphocyte subsets were subsequently sorted by BD FACS
Aria II (ﬁve lasers 355, 405, 488, 561 and 640 nm; BD Bioscience).
Statistics. Samples sizes were chosen based on previous experience in our
laboratory. Statistical analyses were performed in GraphPad Prism version 6.0
software. Statistical signiﬁcance was determined by t-tests (two-tailed) for two
groups or one-way analysis of variance with Bonfferoni’s multiple comparisons
tests for three or more groups. For AIGN model and EAE model, clinical scores
and body weight changes of each treatment group were compared using two-way
analysis of variance. P values ofo0.05 were considered statistically signiﬁcant. No
data were excluded from the statistical analysis.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on request.
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